US biotech dependence on China sparks security fears
TL;DR Summary
Patents expiring for top drugs push Western pharma to partner with Chinese biotech firms, with Pfizer paying up to $650 million for Innovent and Bristol Myers Squibb tying up with Hengrui for up to $950 million, signaling a surge of US investment in Chinese biotech. Lawmakers are weighing tighter national-security rules as the USITC probes potential Chinese state backing, while investors remain divided on the implications for US drug development and global supply chains.
- Growing US reliance on Chinese biotechs prompts national security fears Financial Times
- China’s Rise in Drug Development Looms Over U.S. The New York Times
- China’s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? The Boston Globe
- As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing? Fierce Biotech
- This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced The Motley Fool
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
6 min
vs 7 min read
Condensed
94%
1,231 → 74 words
Want the full story? Read the original article
Read on Financial Times